Steminent Biotherapeutics, Inc.
TTPEX:7729180.00
TWD
+0.50
(+0.28%)
ISIN
TW0007729006
Return %
Stock
S&P 500
1Y
302.08
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Ling Mei Wang
- Full Time Employees
- 55
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 16 WenHu Street Taipei TP Taiwan 11445
- IPO Date
- Mar 11, 2024
- Website
- steminent.com
- Similar Companies
- Business
- Steminent Biotherapeutics Inc. (7729.TWO) operates as a Taiwan-based biopharmaceutical company focused on the research, development, and commercialization of novel stem cell-based therapeutics for degenerative and neurodegenerative diseases with unmet medical needs. The company develops allogeneic mesenchymal stem cell (MSC) products derived from adipose tissue, with its flagship product Stemchymal serving as an intravenous regenerative medicine therapy targeting spinocerebellar ataxia (SCA), including SCA Type 3 and SCA6; Huntington's disease; acute ischemic stroke; knee osteoarthritis; acute liver failure; post-CPR syndrome; and other inflammatory and neurodegenerative conditions such as polyglutamine diseases, Alzheimer's disease, Parkinson's disease, and sequelae of arteriovenous malformation rupture. Stemchymal leverages paracrine effects, immune modulation, anti-inflammatory actions, and tissue repair capabilities through the release of growth factors and cytokines, and the company maintains GMP-compliant manufacturing facilities accredited by Japan's MHLW as a foreign manufacturer for export-ready production. Founded in 2007 and headquartered at No. 12 Wenhu Street, 4F-1, Neihu District, Taipei, Taiwan, Steminent conducts operations across Asia with additional offices in Shanghai, China, and San Diego, California, USA, supporting global clinical development and partnerships in neurology, orthopedics, and systemic inflammatory disease segments targeting patients with moderate-to-severe conditions. In recent developments, Steminent reported positive topline results from its Phase II clinical trials of Stemchymal in April 2025, demonstrating statistically significant disease stabilization and slower progression in SARA scores among SCA3 patients in Taiwan compared to placebo and historical controls, with similar efficacy confirmed in a parallel Japan trial involving SCA3 and SCA6 patients; these findings support planned conditional approval applications in Taiwan and Japan, an FDA Phase IIb submission in the US, and expansion into Huntington's disease. The company listed on the Taipei Exchange (TPEX) emerging stock market in March 2024 following prior public company listing preparations, enhancing its capital access for pipeline advancement. Steminent maintains an exclusive commercialization license agreement with REPROCELL Inc. for Stemchymal in Japan since 2016, alongside regional deals in South Korea and ongoing global partnership discussions in the US, Europe, and Southeast Asia, while showcasing data at international forums like WODC USA 2025 and ISCT 2025.